Vimeo
LinkedIn
Instagram
Share |

roche

September 10, 2015

For decades, wealthy European families have been deploying part of their capital into infrastructure – and often directly into assets. 

For decades, wealthy European families have been deploying part of their capital into infrastructure – and often directly into assets. 

April 12, 2012

Despite tough market conditions, three family businesses from different parts of the world have posted relatively strong quarterly and annual results this week.

Despite tough market conditions, three family businesses from different parts of the world have posted relatively strong quarterly and annual results this week.

European pharmaceutical giant Roche, controlled by the founding family, saw sales for the first quarter of 2012 fall by 1% to CHF11 billion (€9.15 billion) due to the strength of the Swiss franc. However, revenues at constant exchange rate rose by 2%, the Basel-based company said on 12 April.

March 25, 2011

Family-controlled pharmaceutical giant Roche said on 25 March that a member of the family shareholding group has dropped out of the pool, causing the family to lose its voting majority.

Family-controlled pharmaceutical giant Roche said on 25 March that a member of the family shareholding group has dropped out of the pool, causing the family to lose its voting majority.

The Basel, Switzerland-based company said in a statement that family member Maja Oeri, who has 5% voting rights, dropped out of the group – called the voting pool – reducing the family pool’s voting power to 45% from 50%.

February 2, 2011

Swiss pharmaceutical giant Roche announced on 3 February that its full-year net profits rose by 11% year-on-year, despite putting into place a cost saving restructuring program.

Swiss pharmaceutical giant Roche announced on 3 February that its full-year net profits rose by 11% year-on-year, despite putting into place a cost saving restructuring program.

In a statement, the family-controlled company said that its profits increased in 2010 to 8.67 billion Swiss francs (€6.71 billion), from 7.78 billion francs the year before. However, its sales for the year reduced by 3%, attributed to the poor performance of its flu drug Tamiflu.

September 1, 2008

As consumers in Eastern Europe becomes ever more affluent, family businesses around the world are looking to the region for growth rather than cheap land and labour, says Reg Crowder

As consumers in Eastern Europe becomes ever more affluent, family businesses around the world are looking to the region for growth rather than cheap land and labour, says Reg Crowder

Family businesses are increasingly turning to Eastern Europe for growth opportunities. But it's a completely different story from what the world saw in the years following the collapse of the Soviet Union.

November 15, 2007

Roche, the family-owned pharmaceutical firm, has entered into a confidentiality agreement with Ventana Medical Systems and will commence due diligence

Roche, the family-owned pharmaceutical firm, has entered into a confidentiality agreement with Ventana Medical Systems and will commence due diligence. This is in regard to Roche's proposal back in June to acquire all outstanding shares of Ventana for a price of $75 per share.

Ventana rejected the offer in June as "grossly inadequate" but have now allowed due diligence to commence in order to "allow Roche to recognise the significant additional value inherent in Ventana's business".

July 1, 2007

With a production cycle lasting a decade and large conglomerates threatening to swoop, it can be difficult for family-owned pharmaceutical companies to remain both profitable and independent. Andrea Chipman talks to a select few who have made it – Roche, Boehringer, Servier and Stiefel – to learn their strategies for success

Andrea Chipman is a freelance journalist based in the UK.

With a production cycle lasting a decade and large conglomerates threatening to swoop, it can be difficult for family-owned pharmaceutical companies to remain both profitable and independent. Andrea Chipman talks to a select few who have made it – Roche, Boehringer, Servier and Stiefel – to learn their strategies for success

In 2006, the pharmaceutical sector saw another round of consolidation as industry giants gobbled up medium-sized players that had struggled to remain on their own.

March 1, 2005

According to recent research, family firms have stronger ‘people’ values than non-family firms and are more likely to put customers and employees ahead of profits. This doesn’t mean they lose any competitive advantage, argues John Ward

John Ward  is Wild Group Professor of Family Business at IMD in Switzerland and Professor of Family Enterprises at Kellogg School of Management. www.johnlward.com

According to recent research, family firms have stronger 'people' values than non-family firms and are more likely to put customers and employees ahead of profits. This doesn't mean they lose any competitive advantage, argues John Ward

Click here >>
Close